

Göttingen, September 30, 2022

Sartorius completes acquisition of Alumedix

The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has successfully closed the acquisition of Alumedix Ltd. as of September 30, 2022. Alumedix is a leader in the field of recombinant albumin-based solutions and based in Nottingham, UK.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2021, the company earned sales revenue of some 3.45 billion euros. At the end of 2021, nearly 14,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Philipp Grontzki
Head of External Communications
+49 (0)551.308.5581
philipp.grontzki@sartorius.com

Follow Sartorius on Twitter [@Sartorius_Group](#) and on LinkedIn.